ActHIB set to finally reach the Japanese market
This article was originally published in Scrip
Executive Summary
The much-delayed Japanese launch of Sanofi Pasteur-Daiichi Sankyo Vaccines' paediatric meningitis vaccine ActHIB will take place on December 19th. The Haemophilus influenzae type b prophylactic vaccine was approved in the country back in January 2007, but batch production to Japanese standards took longer than expected. The product will be distributed by Daiichi Sankyo, and is not currently eligible for reimbursement under Japan's national insurance scheme.
You may also be interested in...
Japan Regulators Kept On Track Despite Pandemic
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
Need a specific report? 1000+ reports available
Buy Reports